Genetronics engages Quintiles as CRO for US and European clinical trials

Published: 10-Mar-2004

US company Genetronics BioMedical Corporation has contracted Quintiles Transnational Corp., a leading global pharmaceutical services organisation, as the clinical research organisation (CRO) for its clinical trials in the US and Europe for the treatment of head and neck cancer.


US company Genetronics BioMedical Corporation has contracted Quintiles Transnational Corp., a leading global pharmaceutical services organisation, as the clinical research organisation (CRO) for its clinical trials in the US and Europe for the treatment of head and neck cancer.

Quintiles Transnational's product development group provides a full range of drug development and clinical trial management services, from strategic planning to regulatory submission and approval.

'Quintiles' ability to provide integrated global services in the oncology sector and first rate CRO capability will be very beneficial,' said Dr Avtar Dhillon, president and ceo of Genetronics. 'We are excited to have access to Quintiles' expertise in bringing this important new technology forward for registration in the US, launching commercial sales in Europe, and ultimately achieving success in the marketplace.'

  

Trending Articles

You may also like